Literature DB >> 27898595

Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.

Alice L Tseng1, Jonathan Luetkehoelter, Sharon L Walmsley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27898595     DOI： 10.1097/QAD.0000000000001275

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

Review 1.  Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors:  Alice Tseng; Christine A Hughes; Janet Wu; Jason Seet; Elizabeth J Phillips
Journal:  Ann Pharmacother       Date:  2017-06-19       Impact factor: 3.154

2.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Authors:  Parag Kumar; Lori A Gordon; Kristina M Brooks; Jomy M George; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jay Lozier; Colleen Hadigan; Scott R Penzak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 3.  Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.

Authors:  Nicola Squillace; Giorgio Bozzi; Elisa Colella; Andrea Gori; Alessandra Bandera
Journal:  Drug Des Devel Ther       Date:  2018-10-29       Impact factor: 4.162

Review 4.  The challenge of HIV treatment in an era of polypharmacy.

Authors:  David Back; Catia Marzolini
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.